Matches in Nanopublications for { ?s ?p "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- _4 value "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" provenance.
- _4 value "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" provenance.
- _4 value "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" provenance.
- _4 value "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" provenance.
- _4 value "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" provenance.
- _4 value "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" provenance.
- _4 value "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" provenance.
- _4 value "JAK/STATs C225 Phase I treatment (47) AG490 Preclinical treatment (48-51) #----------------------------------------------------------------- Table II. Chemopreventive Agents for Targeting Signal Transduction Pathways Target Drug Phase of Testing Reference Cox-2 Celecoxib Preclinical treatment (164,174-177) and prevention Nimesulide, Valdecoxib, Preclinical treatment (178) Parecoxib, Etoricoxib, Lumaricoxib Sulindac Phase II treatment (179-181) Exisulind Phase I treatment" provenance.